-
admin
Posts
Toll Brothers Announces New Luxury Home Community Coming Soon to Ponte Vedra, Florida
PONTE VEDRA, Fla. , Sept. 05, 2024 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced its newest community, Toll...
New Leadership at Children’s Hospital Colorado to Spearhead Largest Down Syndrome Center in the US
Renowned neurologist Dr. Nicole Baumer takes the helm of the Sie Center for Down Syndrome with a focus on expanding research Denver, Sept. 05, 2024...
Lulus Announces Reduction in Size of its Board of Directors
Board to Transition from Eleven to Six Members Following the Voluntary Resignations of Five Directors CHICO, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) — Lulu’s Fashion...
Mblue Labs, Creator of Skin Health Brand Bluelene, Named One of America’s Top 100 Small Businesses
The U.S. Chamber of Commerce’s CO—100 list celebrates 100 businesses driving growth and innovation in their communities and around the world BETHESDA, Md., Sept. 05,...
Berlin Packaging expands to Japan with the acquisition of Nissho Jitsugyo
Acquisition expands the company’s local footprint in Asia-Pacific and offers exciting new packaging solutions to customers worldwide CHICAGO, Sept. 05, 2024 (GLOBE NEWSWIRE) — Berlin...
Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase I/II Clinical Trial of ATSN-101 in LCA1 Published in The Lancet
First time patients with LCA1 have been treated with gene therapy ATSN-101 demonstrated durable, clinically significant improvements in vision at the high dose and was...
NeuroOne® to Present at the H.C. Wainwright 26th Annual Global Investment Conference
EDEN PRAIRIE, Minn., Sept. 05, 2024 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on...
Amen Clinics & Dr. Daniel Amen Announce Next-Gen Precision Psychiatry 3-Day Conference
Esteemed neuropsychiatrist Dr. Daniel Amen and distinguished experts to teach the Amen Clinics Method at immersive conference IRVING, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) —...
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit...
Oragenics, Inc. Announces Closing of Public Offering
SARASOTA, Fla., Sept. 05, 2024 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of...
